ΠΠΎΡΠ΅ΡΠ½Π°EVGN β’ NASDAQ
add
Evogene Ltd
ΠΡΠ΅ΡΡ
ΠΎΠ΄Π½ΠΎ Π·Π°ΠΊΡΡΡΠ΅Π½ΠΎ
1,67Β $
ΠΠ½Π΅Π²Π½ΠΈ ΠΎΠΏΡΠ΅Π³
1,59Β $ - 1,66Β $
ΠΠΎΠ΄ΠΈΡΡΠΈ ΠΎΠΏΡΠ΅Π³
1,44Β $ - 10,40Β $
Π’ΡΠΆΠΈΡΠ½Π° Π²ΡΠ΅Π΄Π½ΠΎΡΡ
7,95Β ΠΌΠΈΠ». USD
ΠΡΠΎΡΠ΅ΡΠ½Π° ΠΊΠΎΠ»ΠΈΡΠΈΠ½Π°
559,55Β Ρ
ΠΈΡ.
Π¦Π΅Π½Π°/Π·Π°Ρ.
-
ΠΠΎΠ±ΠΈΡ ΠΎΠ΄ Π΄ΠΈΠ²ΠΈΠ΄Π΅Π½Π΄ΠΈ
-
ΠΡΠΈΠΌΠ°ΡΠ½Π° ΡΠ°Π·ΠΌΠ΅Π½Π°
NASDAQ
ΠΠ΅ΡΡΠΈ ΡΠ° ΡΡΠΆΠΈΡΡΠ°
Π€ΠΈΠ½Π°Π½ΡΠΈΡΠ΅
ΠΠΈΠ»Π°Π½Ρ ΡΡΠΏΠ΅Ρ
Π°
ΠΡΠΈΡ
ΠΎΠ΄
ΠΠ΅ΡΠΎ ΠΏΡΠΈΡ
ΠΎΠ΄
(USD) | ΡΠ΅ΠΏ 2024.info | ΠΡΠΎΠΌΠ΅Π½Π° Π/Π |
---|---|---|
ΠΡΠΈΡ
ΠΎΠ΄ | 1,80Β ΠΌΠΈΠ». | -52,32% |
Π’ΡΠΎΡΠΊΠΎΠ²ΠΈ ΠΏΠΎΡΠ»ΠΎΠ²Π°ΡΠ° | 8,17Β ΠΌΠΈΠ». | 9,83% |
ΠΠ΅ΡΠΎ ΠΏΡΠΈΡ
ΠΎΠ΄ | -7,63Β ΠΌΠΈΠ». | -91,52% |
ΠΠ΅ΡΠΎ ΠΏΡΠΎΡΠΈΡΠ°Π±ΠΈΠ»Π½ΠΎΡΡ | -424,83 | -301,69% |
ΠΠ°ΡΠ°Π΄Π° ΠΏΠΎ Π°ΠΊΡΠΈΡΠΈ | -1,31 | -63,75% |
EBITDA | -6,83Β ΠΌΠΈΠ». | -93,87% |
ΠΡΠ΅ΠΊΡΠΈΠ²Π½Π° ΠΏΠΎΡΠ΅ΡΠΊΠ° ΡΡΠΎΠΏΠ° | -0,01% | β |
ΠΠΈΠ»Π°Π½Ρ ΡΡΠ°ΡΠ°
Π£ΠΊΡΠΏΠ½Π° Π°ΠΊΡΠΈΠ²Π°
Π£ΠΊΡΠΏΠ½Π΅ ΠΎΠ±Π°Π²Π΅Π·Π΅
(USD) | ΡΠ΅ΠΏ 2024.info | ΠΡΠΎΠΌΠ΅Π½Π° Π/Π |
---|---|---|
ΠΠΎΡΠΎΠ²ΠΈΠ½Π° ΠΈ ΠΊΡΠ°ΡΠΊ. ΡΠ»Π°Π³Π°ΡΠ° | 19,95Β ΠΌΠΈΠ». | -46,40% |
Π£ΠΊΡΠΏΠ½Π° Π°ΠΊΡΠΈΠ²Π° | 40,11Β ΠΌΠΈΠ». | -30,53% |
Π£ΠΊΡΠΏΠ½Π΅ ΠΎΠ±Π°Π²Π΅Π·Π΅ | 27,88Β ΠΌΠΈΠ». | 27,39% |
Π£ΠΊΡΠΏΠ½Π° Π²ΡΠ΅Π΄Π½ΠΎΡΡ Π°ΠΊΡΠΈΡΠ° | 12,24Β ΠΌΠΈΠ». | β |
ΠΠ΅ΠΈΡΠΏΠ»Π°ΡΠ΅Π½Π΅ Π°ΠΊΡΠΈΡΠ΅ | 6,79Β ΠΌΠΈΠ». | β |
Π’ΡΠΆΠΈΡΠ½Π° ΠΏΡΠ΅ΠΌΠ° Π½ΠΎΠΌΠΈΠ½Π°Π»Π½ΠΎΡ | -2,61 | β |
ΠΠΎΠ²ΡΠ°ΡΠ°Ρ Π°ΠΊΡΠΈΠ²Π΅ | -45,97% | β |
ΠΠΎΠ²ΡΠ°ΡΠ°Ρ ΠΊΠ°ΠΏΠΈΡΠ°Π»Π° | -110,69% | β |
Π’ΠΎΠΊ Π½ΠΎΠ²ΡΠ°
ΠΠ΅ΡΠΎ ΠΏΡΠΎΠΌΠ΅Π½Π° Ρ Π½ΠΎΠ²ΡΡ
(USD) | ΡΠ΅ΠΏ 2024.info | ΠΡΠΎΠΌΠ΅Π½Π° Π/Π |
---|---|---|
ΠΠ΅ΡΠΎ ΠΏΡΠΈΡ
ΠΎΠ΄ | -7,63Β ΠΌΠΈΠ». | -91,52% |
ΠΠΎΡΠΎΠ²ΠΈΠ½Π° ΠΈΠ· ΠΏΠΎΡΠ»ΠΎΠ²Π°ΡΠ° | -4,93Β ΠΌΠΈΠ». | -14,15% |
ΠΠΎΡΠΎΠ²ΠΈΠ½Π° ΠΈΠ· ΠΈΠ½Π²Π΅ΡΡΠΈΡΠ°ΡΠ° | 2,02Β ΠΌΠΈΠ». | -44,68% |
ΠΠΎΡΠΎΠ²ΠΈΠ½Π° ΠΈΠ· ΡΠΈΠ½Π°Π½ΡΠΈΡΠ°ΡΠ° | 4,73Β ΠΌΠΈΠ». | -39,30% |
ΠΠ΅ΡΠΎ ΠΏΡΠΎΠΌΠ΅Π½Π° Ρ Π½ΠΎΠ²ΡΡ | 1,83Β ΠΌΠΈΠ». | -74,18% |
Π‘Π»ΠΎΠ±ΠΎΠ΄Π°Π½ ΡΠΎΠΊ Π½ΠΎΠ²ΡΠ° | 757,88Β Ρ ΠΈΡ. | 124,92% |
ΠΡΠ½ΠΎΠ²Π½ΠΈ ΠΏΠΎΠ΄Π°ΡΠΈ
Evogene is a computational biology company based in Israel. Evogene Ltd. has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence, while adding a deep understanding of biology and advanced biological technologies. Evogene is using its proprietary CPB platform to computationally design and develop next-generation life-science products based upon three core components: microbes, small molecules, and genetic elements.
Evogene's computational platform allows it to substantially increase the probability of successful life-science product development, increase the efficiency and reduce the toxicity of its life-science products while reducing time and cost to development. Its strategic partners include BASF, Bayer, Corteva, ICL Group Ltd. as well as various academic and medical institutions. Wikipedia
ΠΠ·Π²ΡΡΠ½ΠΈ Π΄ΠΈΡΠ΅ΠΊΡΠΎΡ: CEO
ΠΠ°ΡΡΠΌ ΠΎΡΠ½ΠΈΠ²Π°ΡΠ°
2002
ΠΠ΅Π±-ΡΠ°ΡΡ
ΠΡΠΎΡ Π·Π°ΠΏΠΎΡΠ»Π΅Π½ΠΈΡ
142